Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study-Reference-Cited by-同舟云学术

Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study

Published:2021-10-20 Issue: Volume: Page:
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Yang Jin-Ji,Huang Cheng,Fan Yun,Pan Hongming,Feng Jifeng,Jiang Liyan,Li Xing-Ya,Liu Xiao-Qing,Xiong Jian-Ping,Zhao Yan-Qiu,Cheng Ying,Ma Rui,Wang Jie,Wang Yina,Liu Yan-Hui,Lin Dong-Mei,Wang Tao,Shi Wei,Zou Jianjun,Wu Yi-Long^ORCID

Funder

jiangsu hengrui pharmaceuticals co., ltd.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-021-03091-3.pdf

Reference31 articles.

1. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(3):145–164

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424

3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92–98

4. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL et al (2017) Lung cancer: current therapies and new targeted treatments. Lancet 389(10066):299–311

5. Hirsch FR, Suda K, Wiens J, Bunn PA Jr (2016) New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet 388(10048):1012–1024

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis;Clinical and Translational Oncology;2024-04-16

2. Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review;Translational Lung Cancer Research;2024-02

3. First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial;Journal for ImmunoTherapy of Cancer;2024-02

4. Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China;Therapeutic Advances in Medical Oncology;2024-01

5. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis;Therapeutic Advances in Medical Oncology;2024-01